CrossRef Text and Data Mining

Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.

Trends of First-Line Targeted Therapy in Korean Patients With Metastatic Clear Cell Renal Cell Carcinoma: Sunitinib Versus Pazopanib, a Multicenter Study

Minsu Choi, Teak Jun Shin, Byung Hoon Kim, Chun Il Kim, Kyung Seop Lee, Seock Hwan Choi, Hyun Tae Kim, Tae-Hwan Kim, Tae Gyun Kwon, Young Hwii Ko, Yoon Soo Hah, Jae-Shin Park, Se Yun Kwon

Korean J Urol Oncol. 2022;20(2):115-122. Published online 2022 May 26 DOI: https://doi.org/10.22465/kjuo.2022.20.2.115

Trends of First-Line Targeted Therapy in Korean Patients With Metastatic Clear Cell Renal Cell Carcinoma: Sunitinib Versus Pazopanib, a Multicenter Study

Minsu Choi, Teak Jun Shin, Byung Hoon Kim, Chun Il Kim, Kyung Seop Lee, Seock Hwan Choi, Hyun Tae Kim, Tae-Hwan Kim, Tae Gyun Kwon, Young Hwii Ko, Yoon Soo Hah, Jae-Shin Park, Se Yun Kwon

The Korean Journal of Urological Oncology. 2022;20(2):115-122

Link1

Link2 Link3

Re: First-Line Sunitinib versus Pazopanib in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium

M. Pilar Laguna

Journal of Urology. 2017;197(3 Part 1):603-603

Link1 Link2 Link3

Efficacy of first line targeted therapy in real world Korean metastatic renal cell carcinoma patients: Focused on sunitinib and pazopanib

H.S. Chung, E.C. Hwang, D.D. Kwon, J.Y. Park, C.W. Jeong, C. Kwak, C. Song, H.G. Jeon, S.I. Seo, S.-S. Byun, S.-H. Hong, J.S. Chung

European Urology Supplements. 2017;16(10):e2751

Link1 Link2

Pazopanib or Sunitinib? cost-utility analysis of pazopanib versus sunitinib in the first-line treatment of metastatic renal cell carcinoma in Jordan

Abeer A Al-Rabayah, Razan Sawalha, Rawan Fawzi Al Froukh, Rand Al-Bawab, Saad M Jaddoua

Journal of Pharmaceutical Health Services Research. 2021;12(4):566-573

Link1

Link2

A Korean multi-center, real-world, retrospective study of first-line pazopanib in unselected patients with metastatic renal clear-cell carcinoma

Moon Jin Kim, Se Hoon Park, Jae-Lyun Lee, Se-Hoon Lee, Su Jin Lee, Ho Yeong Lim

BMC Urology. 2016;16(1):

Link1

Link2 Link3 Link4

Re: Pazopanib Versus Sunitinib in Metastatic Renal-cell Carcinoma

Idir Ouzaid, Brian Rini

European Urology. 2014;65(3):667-668

Link1 Link2

Can We Translate Non-inferiority Clinical Trial into Practice? Real World Outcome of Sunitinib and Pazopanib as First Line Targeted Therapy in Metastatic Renal Cell Carcinoma: UK Centre Experience

S. Bandyopadhyay, P. Das, J. Davies, L. Puttarachaiah, L. Seneviratne, C. Lawrence

Clinical Oncology. 2020;32(5):e131

Link1 Link2

238O Phase II study of pazopanib as second-line treatment after sunitinib in patients with metastatic renal cell carcinoma

M. Xie, C. He, J. Huang

Annals of Oncology. 2015;26:ix71

Link1 Link2

PCN59 Cost-Effectiveness of Pazopanib Versus Sunitinib and Bevacizumab Associated to Interferon Alpha As First Line Treatments for Metastatic Renal Cell Carcinoma

C. Pepe, L. Paladini, C. Sedlmayer, M. Machado

Value in Health. 2012;15(4):A218

Link1 Link2

Phase II study of pazopanib as second-line treatment after sunitinib in patients with metastatic renal cell carcinoma

Mian Xie, Chaosheng He, Jinkun Huang, Qizhan Lin, Lixin Zou

Annals of Oncology. 2015;26:vii101

Link1 Link2 Link3